Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors
Paulo Siqueira Amaral(Vanderbilt University Medical Center), Brian I. Rini(Vanderbilt University Medical Center), Jennifer Gordetsky(Bipar), Daniel Joyce(Vanderbilt University Medical Center), Daniel A. Barocas(Vanderbilt University Medical Center), Elizabeth Ryan(Cancer Research And Biostatistics), Kathryn E. Beckermann(Vanderbilt University Medical Center), Amy N. Luckenbaugh(Vanderbilt University Medical Center), Sam S. Chang(Memorial Sloan Kettering Cancer Center), Morgan Lambrecht(Vanderbilt University Medical Center), Kerry Schaffer(Vanderbilt University), Kelvin A. Moses(Bristol-Myers Squibb (Germany))
Cited by 5
Related Papers
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
|Journal of Clinical Oncology|2008|907
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
|The Lancet Oncology|2018|658
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)
|Journal of Clinical Oncology|2004|502